ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Outcomes Superior for HM3 LVAD Regardless of Preimplant Strategy drugs
January 16, 2020For patients with advanced heart failure, the HeartMate 3 (HM3) left ventricular assist device (LVAD) is superior to the HeartMate II (HMII), regardless of whether the device is a bridge to transplant (BTT) or a destination therapy (DT) ...
Pharma Sources Insight January 2025
